Anti-obesity drug sibutramine (Reductil) has had its licence suspended and GPs are being asked not to issue any new prescriptions for the drug. The suspension follows a review of the drug’s safety by the European Medicines Agency (EMEA) on the basis of data from the Sibutramine Cardiovascular Outcomes study.
This follows the suspension of the marketing authorisation for Accomplia (Rimonabant) in October 2008. The EMEA decided that the benefits of Acomplia, no longer outweighed its risks.